Research progress of dermatomyositis-related autoantibodies in interstitial lung disease

doi:10.11958/20231512

Abstract

Abstract:

Myositis antibodies are divided into myositis-specific autoantibodies (MSA) and myositis-associated autoantibodies (MAA). There are heterogeneity in the mechanism, clinical features and prognosis of interstitial lung disease (ILD) in the different myositis antibodies. In MSA, anti-melanoma differentiation-related gene 5 (MDA5) antibody and anti-aminoacyl synthetase (ARS) antibody are highly correlated with the occurrence of ILD. Patients with MDA5⁺DM-ILD usually have a rapidly progressive and poor prognosis. The progress of ILD in ARS⁺ DM patients was slow, and the response to treatment is good, but it is easy to relapse. In MAA, anti-Ro52 antibodies often coexist with MSA antibodies, and clinical manifestation is closely related to coexisting antibodies. This review has summarized roles of myositis antibodies in ILD.

Key words: dermatomyositis, interstitial lung disease, antoantibody, clinical features, prognosis

CLC Number:

R593.26

References 38

[1]	DEWANE M E, WALDMAN R, LU J. Dermatomyositis:Clinical features and pathogenesis[J]. J Am Acad Dermatol, 2020, 82(2):267-281. doi:10.1016/j.jaad.2019.06.1309.
[2]	WEN L, CHEN X, CHENG Q, et al. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies:results from a cohort from China[J]. Clin Rheumatol, 2022, 41(11):3419-3427. doi:10.1007/s10067-022-06291-z.
[3]	LIU Y, FENG S, LIU X, et al. IFN-beta and EIF2AK2 are potential biomarkers for interstitial lung disease in anti-MDA5 positive dermatomyositis[J]. Rheumatology(Oxford), 2023:kead117. doi:10.1093/rheumatology/kead117.
[4]	BUENO M, CALYECA J, ROJAS M, et al. Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis[J]. Redox Biol, 2020,33:101509. doi:10.1016/j.redox.2020.101509.
[5]	PHAN T H G, PALIOGIANNIS P, NASRALLAH G K, et al. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis[J]. Cell Mol Life Sci, 2021, 78(5):2031-2057. doi:10.1007/s00018-020-03693-7.
[6]	YE Y, CHEN Z, JIANG S, et al. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5⁺ dermatomyositis with therapeutic implications[J]. Nat Commun, 2022, 13(1):6458. doi:10.1038/s41467-022-34145-4.
[7]	LIANG L, ZHANG Y M, SHEN Y W, et al. Aberrantly expressed galectin-9 is involved in the immunopathogenesis of Anti-MDA5-positive dermatomyositis-associated interstitial lung disease[J]. Front Cell Dev Biol, 2021,9:628128. doi:10.3389/fcell.2021.628128.
[8]	SHIM J A, JO Y, HWANG H, et al. Defects in aminoacyl-tRNA synthetase cause partial B and T cell immunodeficiency[J]. Cell Mol Life Sci, 2022, 79(2):87. doi:10.1007/s00018-021-04122-z.
[9]	SEKIGUCHI A, ENDO Y, YAMAZAKI S, et al. Plasma homocysteine levels are positively associated with interstitial lung disease in dermatomyositis patients with anti-aminoacyl-tRNA synthetase antibody[J]. J Dermatol, 2021, 48(1):34-41. doi:10.1111/1346-8138.15602.
[10]	LI M, ZHANG Y, ZHANG W, et al. Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies[J]. Front Immunol, 2023,14:1169057. doi:10.3389/fimmu.2023.1169057.
[11]	CERIBELLI A, TONUTTI A, ISAILOVIC N, et al. Interstitial lung disease associated with inflammatory myositis:Autoantibodies,clinical phenotypes,and progressive fibrosis[J]. Front Med (Lausanne), 2023,10:1068402. doi:10.3389/fmed.2023.1068402.
[12]	ZAMPELI E, MAVROMMATI M, MOUTSOPOULOS H M, et al. Anti-Ro52 and/or anti-Ro60 immune reactivity:autoantibody and disease associations[J]. Clin Exp Rheumatol, 2020, 38 Suppl 126(4):134-141.
[13]	INUI N, SAKAI S, KITAGAWA M. Molecular pathogenesis of pulmonary fibrosis,with focus on pathways related to TGF-β and the ubiquitin-proteasome pathway[J]. Int J Mol Sci, 2021, 22(11):6107. doi:10.3390/ijms22116107.
[14]	DECKER P, MOULINET T, PONTILLE F, et al. An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management[J]. Autoimmun Rev, 2022, 21(3):103013. doi:10.1016/j.autrev.2021.103013.
[15]	GUI X, SHENYUN S, DING H, et al. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease[J]. Rheumatology (Oxford), 2022, 61(11):4570-4578. doi:10.1093/rheumatology/keac090.
[16]	XU L, YOU H, WANG L, et al. Identification of three different phenotypes in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis patients:implications for prediction of rapidly progressive interstitial lung disease[J]. Arthritis Rheumatol, 2023, 75(4):609-619. doi:10.1002/art.42308.
[17]	MCPHERSON M, ECONOMIDOU S, LIAMPAS A, et al. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease:A systematic review[J]. Semin Arthritis Rheum, 2022,53:151959. doi:10.1016/j.semarthrit.2022.151959.
[18]	WU W, GUO L, FU Y, et al. Interstitial lung disease in anti-MDA5 positive dermatomyositis[J]. Clin Rev Allergy Immunol, 2021, 60(2):293-304. doi:10.1007/s12016-020-08822-5.
[19]	TEEL A, LU J, PARK J, et al. The role of myositis-specific autoantibodies and the management of interstitial lung disease in idiopathic inflammatory myopathies:a systematic review[J]. Semin Arthritis Rheum, 2022,57:152088. doi:10.1016/j.semarthrit.2022.152088.
[20]	GONO T, KUWANA M. Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis[J]. Expert Rev Clin Immunol, 2020, 16(1):79-89. doi:10.1080/1744666x.2019.1699059.
[21]	MARCO J L, COLLINS B F. Clinical manifestations and treatment of antisynthetase syndrome[J]. Best Pract Res Clin Rheumatol, 2020, 34(4):101503. doi:10.1016/j.berh.2020.101503.
[22]	ALBAYDA J, MECOLI C, CASCIOLA-ROSEN L, et al. A North American Cohort of anti-sae dermatomyositis:clinical phenotype,testing,and review of cases[J]. ACR Open Rheumatol, 2021, 3(5):287-294. doi:10.1002/acr2.11247.
[23]	WONG V T, SO H, LAM T T, et al. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies[J]. Acta Neurol Scand, 2021, 143(2):131-139. doi:10.1111/ane.13331.
[24]	TANBOON J, NISHINO I. Update on dermatomyositis[J]. Curr Opin Neurol, 2022, 35(5):611-621. doi:10.1097/WCO.0000000000001091.
[25]	SABBAGH S, PINAL-FERNANDEZ I, KISHI T, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis[J]. Ann Rheum Dis, 2019, 78(7):988-995. doi:10.1136/annrheumdis-2018-215004.
[26]	XING X, LI A, LI C. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis[J]. Respir Med, 2020,172:106134. doi:10.1016/j.rmed.2020.106134.
[27]	GE Y, SHU X, HE L, et al. Interstitial lung disease is a major characteristic of patients who test positive for anti-PM/Scl antibody[J]. Front Med(Lausanne), 2021,8:778211. doi:10.3389/fmed.2021.778211.
[28]	VOJINOVIC T, CAVAZZANA I, CERUTI P, et al. Predictive features and clinical presentation of interstitial lung disease in inflammatory myositis[J]. Clin Rev Allergy Immunol, 2021, 60(1):87-94. doi:10.1007/s12016-020-08814-5.
[29]	ROMERO-BUENO F, DIAZ DEL CAMPO P, TRALLERO-ARAGUÁS E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease[J]. Semin Arthritis Rheum, 2020, 50(4):776-790. doi:10.1016/j.semarthrit.2020.03.007.
[30]	LI X, LIU Y, CHENG L, et al. Roles of biomarkers in anti-MDA5-positive dermatomyositis,associated interstitial lung disease,and rapidly progressive interstitial lung disease[J]. J Clin Lab Anal, 2022, 36(11):e24726. doi:10.1002/jcla.24726.
[31]	SO J, SO H, WONG V T, et al. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis[J]. Rheumatology(Oxford), 2022, 61(11):4437-4444. doi:10.1093/rheumatology/keac094.
[32]	GUI X, LI W, YU Y, et al. Prediction model for the pretreatment evaluation of mortality risk in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease[J]. Front Immunol, 2022,13:978708. doi:10.3389/fimmu.2022.978708.
[33]	AGGARWAL R, CASSIDY E, FERTIG N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients[J]. Ann Rheum Dis, 2014, 73(1):227-232. doi:10.1136/annrheumdis-2012-201800.
[34]	GAN Y Z, ZHANG L H, MA L, et al. Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis[J]. Chin Med J (Engl), 2020, 133(6):644-649. doi:10.1097/cm9.0000000000000691.
[35]	CHEN H, LIU H, LYU W, et al. An observational study of clinical recurrence in patients with interstitial lung disease related to the antisynthetase syndrome[J]. Clin Rheumatol, 2023, 42(3):711-720. doi:10.1007/s10067-022-06424-4.
[36]	HUANG H L, LIN W C, LIN P Y, et al. The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease[J]. Neurol Sci, 2021, 42(7):2855-2864. doi:10.1007/s10072-020-04911-7.
[37]	GONZÁLEZ-PÉREZ M I, MEJÍA-HURTADO J G, PÉREZ-ROMÁN D I, et al. Evolution of pulmonary function in a cohort of patients with interstitial lung disease and positive for antisynthetase antibodies[J]. J Rheumatol, 2020, 47(3):415-423. doi:10.3899/jrheum.181141.
[38]	TAKEI R, YAMANO Y, KATAOKA K, et al. Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease[J]. Respir Investig, 2020, 58(2):83-90. doi:10.1016/j.resinv.2019.10.004.